前列腺癌,病理生理学和管理的最新发展:叙述性审查
Mohamed Nasr Eldeen Almeeri1, Monther Awies1, Constantina Constantinou2
1Department of Basic and Clinical Sciences, University of Nicosia Medical School, 21 Ilia Papakyriakou, 2414 Engomi, P.O. Box 24005, 1700, Nicosia, Cyprus.
晚期前列腺癌的新疗法,包括PARP抑制剂和卢-177,显示出更好的生存率. 目前正在进行的临床试验正在探索新型疗法,以进一步改善前列腺癌患者的治疗结果.
科学领域:
- 在瘤学瘤学.
- 泌尿器科 泌尿器科 泌尿器科 泌尿器科
- 医学研究 医学研究
背景情况:
- 前列腺癌是男性癌症中第二常见的癌症,从局部到转移的不同阶段呈现.
- 治疗策略根据癌症的阶段有很大的不同,包括局部,局部晚期,非转移性抵抗割的前列腺癌 (M0 CRPCa) 和转移性疾病.
研究的目的:
- 对前列腺癌不同阶段的现有和新兴治疗方法进行审查.
- 要突出最近在治疗转移性割抵抗性前列腺癌 (mCRPCa) 的药物开发方面的进展.
主要方法:
- 对局部,局部晚期,M0 CRPCa和转移性前列腺癌的当前治疗选择的审查.
- 对最近批准的药物和正在进行的前列腺癌临床试验进行分析.
主要成果:
- 对于M0 CRPCa和无激素转移性前列腺癌,治疗方法包括使用阿帕胺,达罗胺或恩扎胺等药物进行雄激素剥夺疗法.
- 对于转移性割抵抗性前列腺癌 (mCRPCa),用于减缓进展的治疗方法包括sipuleucel-T,-223,abiraterone,enzalutamide和cabazitaxel.
- 最近批准的mCRPCa药物,包括PARP抑制剂和卢-177,在整体存活率和无放射性进展存活率上显著改善.
结论:
- 目前的治疗方法为各种前列腺癌阶段提供了良好的结果,在治疗晚期疾病方面取得了显著进展.
- 新兴的治疗方法,如PARP抑制剂,卢泰-177,以及临床试验中的疗法 (例如,卡博桑提尼布,CAR T细胞疗法),有望改善晚期前列腺癌的生存率和无进展生存率.
更多相关视频
13:19Microarray-based Identification of Individual HERV Loci Expression: Application to Biomarker Discovery in Prostate Cancer
Published on: November 2, 2013
07:34Author Spotlight: Advancing Prostate Cancer Research Through Improved Tissue Sampling and Biobanking
Published on: November 17, 2023
相关概念视频
Tumor Progression
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...
Cancer Survival Analysis
Targeted Cancer Therapies
There are several types of targeted therapies against...
Disorders of the Male Reproductive System
Prostate disorders are another major concern. These conditions can impair urinary flow due to the prostate's location around the urethra....
Cancer
Cancer Stem Cells and Tumor Maintenance
Cancer stem cells are thought to originate from tissue-specific normal stem cells or progenitor cells. The normal stem cells usually reside in...
